Mankind Pharma IPO Listing: Shares Debut with a 20 Percent Premium

Mankind Pharma IPO Listing: Shares Debut with a 20% Premium

Mankind Pharma (MANKIND) made a stellar debut in the stock market with its IPO listing. The shares started their secondary market journey at Rs.1,300 per share, a 20% premium over the issue price. 

Let's take a closer look at Mankind Pharma's IPO listing, its financial performance, and what it means for investors.

About Mankind Pharma

Mankind Pharma is a leading pharmaceutical company based in India. The company was founded in 1995 and offers a wide range of high-quality medicines and healthcare products across various therapeutic categories. 

Mankind Pharma has a strong presence in both domestic and international markets, and its products are available in more than 22 countries around the world.

Mankind Pharma IPO Details

Mankind Pharma's IPO was oversubscribed by more than 2.5 times, indicating strong investor interest. 

The IPO consisted of a fresh issue of shares worth Rs 1,250 crore and an offer for sale (OFS) of shares worth Rs 2,500 crore by the promoters. The issue price of the shares was set at Rs 1,075 per share.

Mankind Pharma IPO Listing Details

Mankind Pharma's shares were listed on both BSE and NSE. The shares debuted at a price of Rs 1,300 apiece, a 20% premium over the issue price of Rs 1,075 per share. 

The market capitalization of the company stood at Rs 49,000 crore at the time of listing.

Mankind Pharma's Financial Performance

Mankind Pharma has a strong financial performance, as evident from its past financial records. 

The company's revenue has been growing consistently over the past few years. In FY2021, the company's revenue stood at Rs 8,668 crore, up from Rs 5,087 crore in FY2018. 

The net profit of the company has also been growing at a steady pace, with the company reporting a net profit of Rs 2,000 crore in FY2021, up from Rs 1,034 crore in FY2018.
 

Should You Invest in Mankind Pharma?

Mankind Pharma's strong presence in the pharmaceutical industry, coupled with its robust financials, makes it an attractive investment opportunity. 

The company has a diversified product portfolio, a wide distribution network, and a strong R&D focus. The company's international presence also provides a good opportunity for growth in the future.

However, as with any investment decision, it is always important to conduct thorough research and analysis before making any investment decisions. Investors should also keep in mind the risks associated with investing in the stock market, such as market volatility, geopolitical risks, and company-specific risks.

To Sum Up..

Mankind Pharma's IPO listing has been a success, with its shares debuting with a 20% premium over the issue price. 

The company's strong financial performance and growth potential make it an attractive investment opportunity for investors looking to invest in the pharmaceutical industry. 

However, investors should always conduct their own research and analysis before making any investment decisions.

FAQs

1) Is Mankind Pharma listed?
Ans - Based on the information available on the BSE website, it has been announced that Mankind Pharma's share price will be listed on both the NSE and BSE on May 9th, 2023. The IPO listing date for Mankind Pharma has been confirmed for Tuesday, May 9th, 2023, and the listing will occur during a special pre-open session. Please note that my knowledge is based on information up until September 2021, and I cannot provide real-time updates on specific events or listings.

2) What is the price of Mankind Pharma IPO share listing?
Ans - On Tuesday, the shares of Mankind Pharma were listed at a price of Rs 1,300 per share, which was 20.37% higher than the IPO price of Rs 1,080.

3) Which IPO was listed on a premium of 53 percent?
Ans - Zomato made a robust entry into the stock market, with its IPO listing at a premium of more than 53 percent over the issue price.

4) What is the future of Mankind Pharma stock?
Ans - Mankind's projected revenue growth of 12.2% per year surpasses the expected growth rate of the Indian market, which is 10.2% per year. However, in terms of high growth revenue, Mankind's anticipated growth of 12.2% per year is slower compared to the target of 20% per year.

5) What is grey market premium of mankind Pharma Ltd?
Ans - According to the grey market trends, Mankind Pharma is expected to debut on the stock market on May 9 with a premium of Rs 120 per share. The company has a market capitalization of Rs 44,000 crore and is valued at a price-to-earnings ratio of 30 times FY22 earnings.